Presents information on the apparent decline in clinical medicine in Britain, one of Britain's traditional strengths. Analysis by the Institute for Scientific Information (ISI); Clinicians staying out of research because of decline in salaries; Increase in `soft money' from drug companies and small charities accounting for drop in quality and jump in output, according to Edinburgh gastroenterologist Ian Bouchier.
The article discusses the finding of the trachea surgeon Paolo Macchiarini guilty by the Karolinska Institute (KI) in Stockholm, Sweden for scientific misconduct, commenting on his patients' deaths due to faulty artificial trachea and the retraction of papers he authored.
Reports on the analysis of papers published by the National Institutes of Health (NIH) intramural scientists between 1981-1993. Citation impact of NIH papers relative to US biomedical baseline; Anecdotal evidence of decline; Proportion of NIH papers mentioned in most cited biomedical articles in the world.
*DRUGS, *MEDICINE, *MEDICAL care, *ANTIBIOTICS, *SCIENCE, *DIAGNOSIS
Abstract
The article presents several corrections related to science that appear in the December 2004 issue of the journal "Science." The paper "New TB Drug Promises Shorter, Simpler Treatment," by J. Cohen incorrectly stated that Johnson & Johnson was screening for a broad spectrum antibiotic. The company was screening for a TB drug from the outset. The researchers also found resistance to their new compound in vitro, not in the mouse model. The image credit was incorrect. The credit should be KeesVeenenbos.
Presents findings from a study which suggests that Indian biomedical scientists are focusing on the diseases of the affluent at the expense of their own country's health problems. Study looked at the topics of over 1000 papers published by Indian biomedical doctors between 1987 and 1994; Most common subjects relating to cancer, cardiovascular disease, and tropical diseases; The fact that Indian biomedical research suffers from general low quality.